ALVO vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ALVO's deterministic health scores signal significant distress: the Piotroski F-Score of 2/9 indicates weak financial health, with poor profitability, negative operating margins, and erratic earnings. The absence of an Altman Z-Score raises red flags for potential bankruptcy risk, especially given negative operating margins and a low quick ratio of 0.54. Despite a modest 10.6% YoY revenue growth and a 55.59% gross margin, the company exhibits severe earnings instability, with a -161.1% YoY EPS decline and multiple quarters of massive negative surprises. The stock trades at a premium to its intrinsic value of $1.61, suggesting overvaluation based on current fundamentals. Analysts' target price of $18.83 appears disconnected from current performance and financial health.
JNJ shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ALVO vs JNJ: Head-to-Head Comparison
This page compares Alvotech (ALVO) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.